Pt modified BaZr_0.76Y_0.2Ni_0.04O₃ (BZYN) is fabricated and characterized as a stable electrolyte for proton-conducting solid oxide fuel cell (H-SOFC). The utilization of X-ray diffraction method (XRD) and transmission electron microscopy (TEM) enables the identification of the presence of platinum (Pt) in both the crystal lattice sites and the grain interface. This occurrence contributes to a reduction in grain boundary resistance. Consequently, this phenomenon improves the conductivity of the electrolyte. The electrochemical performance of the single cell with Pt modified BZY electrolyte is improved by the reduction of ohmic resistance and enhancement of ion migration. This signifies a noteworthy advancement in the creation of more efficient and durable proton-conducting SOFCs.

Based on the marine natural products piperafizine B, X334 and our previously reported compound 4m, fourteen novel 3,6-diunsaturated 2,5-diketopiperazine (2,5-DPK) derivatives (1-2, 4-6, 8-16), together with two known ones (3 and 7), were designed and synthesized as anticancer agents against cell lines A549 and Hela. The MTT assay results showed that the derivatives 6, 8-12 and 15 had moderate to good anticancer capacities with the IC50 values ranging from 0.7 to 8.9 μM. Among them, compound 11 with naphthalen-1-ylmethylene and 2-methoxybenzylidene functions at the 3- and 6-positions of 2,5-DPK ring, respectively, displayed good inhibitory activities to both cancer cells A549 (IC50 = 1.2 μM) and Hela (IC50 = 0.7 μM). It could also induce apoptosis and obviously block the cell cycle progression at G2/M phase in both cells at 1.0 μM. The electron withdrawing functions might not be favorable for the derivatives with high anticancer activities. Additionally, compared to piperafizine B and X334, these semi-N-alkylated derivatives have high liposolubilities (> 1.0 mg•mL-1). Compound 11 can be further developed aiming to the discovery of novel anticancer candidate.